Kevin M. Jude

The paper shows that TCR germline sequences encode MHC restriction, revealing a structural basis for TCR recognition of MHC molecules independent of antigenic peptide.

The paper determines structural states of the US28-Gq complex to elucidate a stepwise G protein activation mechanism.

A fully orthogonal IL-2 receptor platform isolates 36 cytokine receptors in T cells; receptor-specific STAT combinations specify distinct fates, and STAT3-dominant programs give curative antitumor responses.

This study develops a receptor-tethered orthogonal IL-2 system to enhance Treg persistence and efficacy in autoimmune diabetes, showing improved survival and therapeutic outcomes.

This paper designs soluble, miniaturized MHC proteins that enable stable expression in E. coli and retain peptide and TCR binding specificity.

The paper shows that T cells engineered with IL-9R have better tissue infiltration, stemness, and anti-tumor activity compared to those with an orthogonal IL-9 receptor, due to stronger and more specific JAK/STAT signaling.

This paper introduces ADAPT, a deep learning framework for designing TCRs and antibodies that bind to specific pMHC targets, validated through cryo-EM structures and functional testing.

This paper describes a designed IL-21 mimic, 21h10, which shows potent antitumor activity in multiple models and reduces toxicity through TNF blockade.

A de novo four-helix bundle designed with RFdiffusion and ProteinMPNN binds NY-ESO-1/HLA-A*02 at Kd 9.5 nM, with a 2.05 Å crystal structure and peptide-focused docking.

This paper introduces TRACeR-II, a platform for developing MHC-II binders using a single loop, demonstrating its versatility and applicability to SARS-CoV-2 peptides.

This paper designs small, stable proteins that bind to diverse target proteins using only structural information, achieving nanomolar to picomolar affinities.